Partner Headlines - AMGN

  1. Leerink Is Back On Board The Biotech Train

    Benzinga
  2. LinkedIn Downgraded; Biotechs Initiated; Tableau PT Cut

    IBD
  3. Plenty of Opportunity to Buy Individual Stocks: John Buckingham

    GuruFocus
  4. Maybe Some Good News For A Big Biotech ETF

    Benzinga
  5. Why Amazon, Microsoft, Xerox And Amgen Are Moving After-Hours

    Benzinga
  6. Earnings Recap For January 28

    Benzinga
  7. FDA Accepts Amgen's Biosimilar Biologics License Application ...

    Benzinga
  8. Regeneron Is Now A Sell For Chardan

    Benzinga
  9. Big Earnings Expectations For Big Biotech

    Benzinga
  10. Amgen's Vectibix, Best Supportive Care Improves Overall Survival ...

    Benzinga
  11. Amgen's Repatha) Approved in Japan as First PCSK9 Inhibitor for ...

    Benzinga
  12. Medicines Company Spikes On Report Of Possible Sale

    IBD
  13. Jim Cramer Likes Amgen

    Benzinga
  14. Write A Prescription For This Healthcare ETF

    Benzinga
  15. Stocks Reverse Higher To Big Gains; Intel Falls After Q4 Results

    IBD
  16. Stocks, Mutual Funds Rose In Q4 Despite Dec. Woes

    IBD
  17. Jim Cramer Gives His Opinion On Lockheed Martin And Gilead Sciences

    Benzinga
  18. 3 Potential Blockbuster Drugs Launching in 2016

    IBD
  19. Mid-Afternoon Market Update: Netflix Drops Following Baird Downgrade; ...

    Benzinga
  20. Mid-Day Market Update: Baxalta Shares Surge Amid Report Of Shire ...

    Benzinga
  21. Mid-Morning Market Update: Markets Open Lower; Tesla Motors Delivers ...

    Benzinga
  22. Benzinga's Top #PreMarket Gainers

    Benzinga
  23. Alan Fournier Sells GM, Buys Molson Coors Brewing

    GuruFocus
  24. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD
  25. Dividend Growth Skids To Halt For S&P 500

    IBD
  26. 5 Guru Picks in Volatile Biotech Industry

    GuruFocus
  27. Benzinga's M&A Chatter for Monday December 21, 2015

    Benzinga
  28. Big Cap 20 Stocks Setting Up In Bases

    IBD
  29. Analyzing Amgen's Dividend Hike

    GuruFocus
  30. 3 Biotechs Atlantic Equities Loves And 1 It's Avoiding

    Benzinga
  31. Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma ...

    Benzinga
  32. EC Approves Amgen's IMLYGIC as First Oncolytic Immunotherapy ...

    Benzinga
  33. 4 Top Dividend Plays To Help Cure Stock Price Blues

    IBD
  34. Big Biotech Amgen Facing Pivotal Year In 2016

    IBD
  35. Allergan Among Health Care Holdings in Alan Fournier's Portfolio

    GuruFocus
  36. Benzinga's Top Upgrades

    Benzinga
  37. Benzinga's Top #PreMarket Gainers

    Benzinga
  38. Amgen Shares Move Higher Following Morgan Stanley Upgrade To ...

    Benzinga
  39. Amgen Submits Application to EMA To Expand Indication Of Kyprolis ...

    Benzinga
  40. Amgen Announces New Analyses Presented At #ASH2015 Demonstrate ...

    Benzinga
  41. Amgen Announces Pivotal Head-To-Head ENDEAVOR Study Results Published ...

    Benzinga
  42. Amgen, Merck target cancer

    IBD
  43. Amgen Expands Work With Merck, Files Biosimilar In EU

    IBD
  44. LinkedIn, Palo Alto, Regeneron Profit Estimates Rising

    IBD
  45. Application for Amgen's Biosimilar Candidate to Humira, Submitted ...

    Benzinga
  46. Benzinga's M&A Chatter for Tuesday December 1, 2015

    Benzinga
  47. Biotechs Weaken, But These Names Have Bullish Charts

    IBD
  48. EC Approves Amgen's BLINCYTO for Treatment of Adults with Philadelphia ...

    Benzinga
  49. CVS Makes Amgen New BFF

    IBD
  50. CVS' Amgen Pick 'Raises The Bar' For Regeneron, Sanofi

    IBD
  51. European Commission Approves Kyprolis® (carfilzomib) For Combination ...

    Benzinga
  52. PRIMECAP Sells Stake in Technology Company

    GuruFocus
  53. Regeneron Tests Buy Point As New Drug Shows Promise

    IBD
  54. Regeneron Recovers From Clinton Biotech Beat Down

    IBD
  55. Benzinga's M&A Chatter for Tuesday November 10, 2015

    Benzinga
  56. Amgen Issues Presentation of Results from Phase 3 Study Showing ...

    Benzinga
  57. Amgen Announces Etelcalcetide Met Primary Endpoint of Non-Inferiority ...

    Benzinga
  58. ICYMI: Berkshire Hathaway Just Reported Earnings Of $2,769 Per ...

    Benzinga
  59. ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray

    Benzinga
  60. Regeneron Q3 Beats Views, But Praluent Launch Slow

    IBD
  61. AbbVie Beats Q3 Views, Offers Bullish 2020 Guidance

    IBD
  62. 10 Stocks To Watch For October 29, 2015

    Benzinga
  63. Buffalo Wild, GoPro Among Flurry Of Late Wed. Earnings

    IBD
  64. Amgen Crushes EPS Views

    IBD
  65. Amgen Q3 Earnings Beat; Sales Growth Best In Years

    IBD
  66. Amgen Posts Upbeat Q3 Results, Lifts Forecast

    Benzinga
  67. Lifelock, Yelp Surge Following Earnings Report; B-Dubs, GoPro ...

    Benzinga
  68. Wild Short Interest Swings For Three Top Biotech Stocks

    Benzinga
  69. Keep an Eye on These 10 Stocks for October 28, 2015

    Benzinga
  70. Stocks End Lower; Apple Up, Twitter Down After Hours

    IBD
  71. Amgen and Cytokinetics Announce Positive Top-Line Results From ...

    Benzinga
  72. Biotech ETFs: Buy, Buy, Buy?

    Benzinga
  73. 10 S&P 100 Companies Paying The Highest And Lowest Taxes

    Benzinga
  74. Amgen Receives CHMP Positive Opinion For IMLYGIC™ (Talimogene ...

    Benzinga
  75. Cowen: In Biotech Earnings We Trust

    Benzinga
  76. Valeant Subpoenaed By Federal Prosecutors On Pricing

    IBD
  77. Valeant Subpoenaed By Federal Prosecutors On Pricing

    IBD
  78. Biotech ETFs Get More Refined With Debut Of Cancer Immunotherapy ...

    Benzinga
  79. Eli Lilly Pulls Cholesterol Drug

    IBD
  80. AMGEN

    IBD
  81. After-Hours Action: JetBlue, Amgen, Medtronic

    IBD
  82. New Exploratory Analysis Showed Romosozumab Increased Estimated ...

    Benzinga
  83. Regeneron Stock Pops But Hits Resistance At 50-Day

    IBD
  84. Lilly Kills 'High Risk/High Reward' Cholesterol Drug

    IBD
  85. Eli Lilly Discontinues Evacetrapib; Investors Move Bets To Alternatives

    Benzinga
  86. Amgen Announces New Data Show Greater Bone Mineral Density Gains ...

    Benzinga
  87. Benzinga's M&A Chatter for Wednesday October 7, 2015

    Benzinga
  88. A Cholesterol Drug Revolution

    IBD
  89. Amgen's 1990 Base Breakout Launched Major Price Move

    IBD
  90. Stocks Fade After Solid Start; Tesla, Adobe Weigh On Nasdaq

    IBD
  91. Regeneron, Amgen Up As PCSK9s Gain Key Coverage

    IBD
  92. Stocks Surge In Mixed Volume; Amgen, Global Payments Rocket

    IBD
  93. Are Cholesterol Drugs In For Another Revolution?

    IBD
  94. EXPRESS SCRIPTS

    IBD
  95. Amgen Announces Repatha™ Co-Preferred Position on Express Scripts ...

    Benzinga
  96. Biotech Bears Spark Good Vibes For These ETFs

    Benzinga
  97. Genomics Out Of 'Caveman Era,' But Still A Ways To Go

    IBD
  98. US Stock Futures Up; All Eyes On Jobs Report

    Benzinga
  99. FDA Accepts Novartis/Sandoz Regulatory Submission for Proposed ...

    Benzinga
  100. Fast Money Traders Share The Stocks They Would Buy In Fourth ...

    Benzinga
Trading Center